Orion Oyj (ORNBV) - Financial and Strategic SWOT Analysis Review

August 2017 | 63 pages | ID: OB75F0E319DEN
GlobalData

Abstracts

Orion Oyj (ORNBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orion Oyj (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Oyj Key Recent Developments

Jul 19,2017: Orion Group Half-Year Financial Report January-June 2017
Apr 26,2017: Orion Group Interim Report January–March 2017
Apr 11,2017: Pharmaceutical leader Orion selects Determine to optimize their global Source-to-Contract effectiveness
Feb 13,2017: Change in Orion Group Executive Management Board as of 21 February 2017
Feb 10,2017: Orion Research Foundation grants EUR 1 million for research

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Orion Oyj - Key Facts
Orion Oyj - Key Employees
Orion Oyj - Key Employee Biographies
Orion Oyj - Major Products and Services
Orion Oyj - History
Orion Oyj - Company Statement
Orion Oyj - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Orion Oyj - Business Description
Orion Oyj - Corporate Strategy
Orion Oyj - SWOT Analysis
SWOT Analysis - Overview
Orion Oyj - Strengths
Orion Oyj - Weaknesses
Orion Oyj - Opportunities
Orion Oyj - Threats
Orion Oyj - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Orion Oyj, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017
Apr 26, 2017: Orion Group Interim Report January–March 2017
Apr 11, 2017: Pharmaceutical leader Orion selects Determine to optimize their global Source-to-Contract effectiveness
Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017
Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research
Feb 08, 2017: Orion Group Financial Statement Release for 2016
Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017
Oct 25, 2016: Orion Group Interim Report January-September 2016
Jul 19, 2016: Orion Group Half-Yearly Report January-June 2016
Jun 15, 2016: Orion upgrades full-year outlook for 2016

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Orion Oyj, Key Facts
Orion Oyj, Key Employees
Orion Oyj, Key Employee Biographies
Orion Oyj, Major Products and Services
Orion Oyj, History
Orion Oyj, Subsidiaries
Orion Oyj, Key Competitors
Orion Oyj, Ratios based on current share price
Orion Oyj, Annual Ratios
Orion Oyj, Annual Ratios (Cont.1)
Orion Oyj, Annual Ratios (Cont.2)
Orion Oyj, Interim Ratios
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Orion Oyj, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Orion Oyj, Performance Chart (2012 - 2016)
Orion Oyj, Ratio Charts
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Orion Oyj, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Tasly Pharmaceuticals Inc
Merck & Co Inc
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Biotie Therapies Corp
Biohit Oyj
Abbott Laboratories Inc.